Biosimilars – Emerging Biosimilars – Immunology: Inflectra/Remsima Launch Tracking (Germany) Wave 2

LaunchTrends®: Inflectra/Remsima (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two different brands of Celltrion’s infliximab biosimilar CT-P13.

Rheumatologists and gastroenterologists in Germany were surveyed to determine their level of awareness of and experience and satisfaction with Inflectra and Remsima, to identify key drivers and barriers to the uptake of these agents, and to gauge physicians’ level of contact with marketers of infliximab biosimilars and Remicade.”

Questions Answered:

  • This survey was fielded in November 2015, six months after the initial survey (Wave 1) and approximately nine months after the launch of Inflectra and Remsima in Germany. Since Wave 1, how have awareness and perceptions of infliximab biosimilars changed among German rheumatologists and gastroenterologists?
  • Physicians may prescribe a biosimilar to patients who are initiating biological treatment or switch patients mid-treatment from a branded biologic. Among German rheumatologists and gastroenterologists, what are the key drivers for prescribing Inflectra/Remsima, and what proportion of patients are switched to these agents from Remicade?
  • Regulatory frameworks exist within the German healthcare system to drive uptake of less-expensive versions of branded medicines, including biosimilars. What proportion of German rheumatologists and gastroenterologists has been actively encouraged to use Inflectra/Remsima or to meet a prescribing quota for these agents?
  • The availability of other biosimilars will likely play a key role in determining the future use of Inflectra/Remsima and Remicade. What benefit would another infliximab biosimilar need to offer for German rheumatologists and gastroenterologists to preferentially prescribe it in place of Inflectra/Remsima?

Scope:

Markets covered: Germany.

Primary research: Online survey of 30 gastroenterologists and 30 rheumatologists in Germany.

Table of contents

  • Biosimilars - Emerging Biosimilars - Immunology: Inflectra/Remsima Launch Tracking (Germany) Wave 2
    • Key Findings
      • Awareness and Perceptions of Inflectra/Remsima
      • Inflectra/Remsima Trial and Use
      • Strategies to Drive Biosimilar Use in Germany
      • Infliximab Promotional Activity
      • Future Use of Other Biosimilars and Brands
      • Differences Between Biosimilar Prescriber and Nonprescriber Profiles: RA
        • Differences Between Biosimilar Prescriber and Nonprescriber Profiles: CD
        • Inflectra/Remsima Awareness and Perceptions
          • Unaided Awareness of Biologics for the Treatment of RA, PsA, and AS
            • Biologics Cited for RA
            • Biologics Cited for PsA
            • Biologics Cited for AS
          • Unaided Awareness of Biologic Drugs for the Treatment of CD and UC
            • Biologics Cited for CD
            • Biologics Cited for UC
          • Level of Familiarity with Biosimilars, Inflectra, and Remsima
            • Level of Familiarity
          • Level of Familiarity with Biosimilars: Wave 1 vs. Wave 2
            • Mean Level of Familiarity by Wave
          • Physician-Reported Net Cost of Inflectra and Remsima
            • Physician-Reported Average Net Cost of Inflectra and Remsima Below Remicade Cost
          • Physician Perception of Indications in Which Inflectra/Remsima Was Studied
            • Indications in Which Physicians Believe Inflectra/Remsima Was Clinically Studied Prior to EMA Approval - Gastroenterologists
            • Indications in Which Physicians Believe Inflectra/Remsima Was Clinically Studied Prior to EMA Approval - Rheumatologists
          • Physician Awareness of Inflectra/Remsimau2019s Approved Indications
            • Indications for Which Physicians Believe Inflectra/Remsima Has EMA Approval - Gastroenterologists
            • Indications for Which Physicians Believe Inflectra/Remsima Has EMA Approval - Rheumatologists
          • Information on Inflectra/Remsimau2019s Development
            • Physician Opinion of Appropriateness of Inflectra/Remsimau2019s Approval
              • Indications for Which Physicians Believe Inflectra/Remsima Should Have Been Approved - Gastroenterologists
              • Indications for Which Physicians Believe Inflectra/Remsima Should Have Been Approved - Rheumatologists
          • Inflectra/Remsima Usage and Experience
            • Prescription of Inflectra for CD or UC: Gastroenterologists
              • CD and UC Patients Prescribed Inflectra by Gastroenterologists
            • Prescription of Remsima for CD or UC: Gastroenterologists
              • CD and UC Patients Prescribed Remsima by Gastroenterologists
            • Prescription of Inflectra for RA, AS, or PsA: Rheumatologists
              • RA, AS, and PsA Patients Prescribed Inflectra by Rheumatologists
            • Prescription of Remsima for RA, AS, or PsA: Rheumatologists
              • RA, AS, and PsA Patients Prescribed Remsima by Rheumatologists
            • Prescription of Inflectra in Rheumatology and Gastroenterology
              • Percentage of Physicians Who Have Prescribed Inflectra for Any Indication
            • Prescription of Remsima in Rheumatology and Gastroenterology
              • Percentage of Physicians Who Have Prescribed Remsima for Any Indication
            • Prescription of Any Biosimilar in Rheumatology and Gastroenterology
              • Percentage of Physicians Who Have Prescribed Any Infliximab Biosimilar for Any Indication
              • Percentage of Patients Under Management Prescribed Any Infliximab Biosimilar for Any Indication
            • Prevalence of Switching and Biosimilar Use in Treatment-Naive Patients
              • Proportion of Inflectra/Remsima-Treated Patients Who Were Biologic-Naive or Switched from Another Biologic
            • Level of Satisfaction with Inflectra and Remsima
              • Similarity of Inflectra/Remsima to Remicade
                • Physician Perception of Inflectra/Remsimau2019s Similarity to Remicade
              • Reasons for Prescribing Inflectra
                • Reasons for Choosing to Prescribe Inflectra
              • Reasons for Prescribing Remsima
                • Reasons for Choosing to Prescribe Remsima
              • Reasons for Not Using Inflectra
                • Reasons for Not Using Remsima
                  • Timing Expectations of Inflectra Prescription
                    • Timing Expectations for the Prescription of Inflectra
                  • Timing Expectations of Remsima Prescription
                    • Timing Expectations for the Prescription of Remsima
                  • Reasons for Timing Expectation to Start Prescribing Inflectra/Remsima
                    • Timing Expectation to Start Prescribing Inflectra/Remsima: Gastroenterologists
                    • Timing Expectation to Start Prescribing Inflectra/Remsima: Rheumatologists
                  • Patient Acceptance of Inflectra/Remsima
                    • Percentags of Patients Who Accepted Inflectra/Remsima Following Physician Proposal
                • External Factors Affecting Inflectra/Remsima Use
                  • Prevalence of Recommendations for the Use of Inflectra/Remsima
                    • Recommendations for the Use of Inflectra/Remsima
                  • Encouraging Use of Inflectra
                    • Factors That Would Encourage Use of Biosimilar Infliximab: Inflectra
                    • Rheumatologists
                  • Encouraging Use of Remsima
                    • Factors That Would Encourage Use of Biosimilar Infliximab: Remsima - Gastroenterologists
                    • Factors That Would Encourage Use of Biosimilar Infliximab: Remsima - Rheumatologists
                  • Expectations for a Biosimilar Infliximab Prescribing Quota
                    • Encouragement and Expectations to Meet Prescribing Quota
                    • Expected Prescribing Quota for Biosimilar Infliximab Among Total Infliximab Molecules Prescribed
                  • Expectations for Reference Pricing: Gastroenterologists
                    • Expectation for Creation of a Reference Price Group Following Inflectra/Remsima Launch: Gastroenterologists
                  • Expectations for Reference Pricing: Rheumatologists
                    • Expectation for Creation of a Reference Price Group Following Inflectra/Remsima Launch: Rheumatologists
                • Promotional Activity
                  • Sales Representativesu2019 Last Contact: Inflectra
                    • Timing of Sales Representativesu2019 Last Contact: Inflectra (Hospira)
                  • Sales Representativesu2019 Last Contact: Remsima
                    • Timing of Sales Representativesu2019 Last Contact: Remsima (Mundipharma)
                  • Sales Representativesu2019 Last Contact: Remicade
                    • Timing of Sales Representativesu2019 Last Contact: Remicade (MSD)
                  • Sales Representativesu2019 Topics of Discussion: Gastroenterologists
                    • Sales Representativesu2019 Topics of Discussion: Rheumatologists
                    • Future Use of Biosimilars
                      • Influence of Inflectra/Remsima Experience on Use of Future Biosimilars
                        • Likelihood of Using Other Biosimilars After Experience with Inflectra/Remsima: Gastroenterologists
                        • Likelihood of Using Other Biosimilars After Experience with Inflectra/Remsima: Rheumatologists
                      • Physician Likelihood of Prescribing Other Infliximab Biosimilars
                        • Likelihood of Prescribing Another Infliximab Biosimilar: All Physicians
                        • Likelihood of Prescribing Another Infliximab Biosimilar: Wave 1 vs. Wave 2
                      • Current and Future CD Patient Share
                        • Current and Future CD Patient Share Assuming No Further Biosimilars Launch
                      • Current and Future RA Patient Share
                        • Current and Future RA Patient Share Assuming No Further Biosimilar Launches
                    • Appendix
                      • Market News, Background, Methodology, and Objectives
                        • EU TNF-Alpha Inhibitor Market News
                        • The Celltrion Partnership Network
                        • Market Background: EU Milestones for Inflectra/Remsima
                        • Market Background: European Assessment of Inflectra/Remsima
                        • Physician Research Methodology
                        • Significance Testing in This Study
                        • Abbreviations
                        • Objectives
                      • Biologics Approved for Rheumatic Diseases and IBD in Europe
                        • Biologics Approved for Rheumatic Diseases in Europe
                          • German Pricing and Reimbursement
                            • Background on Reimbursement in Germany
                            • Biosimilars Pricing in Germany
                            • German Pharmacy Retail Prices for Infliximab (5x100 mg)
                            • Minimum Prescribing Quotas for Biosimilar Infliximab (2016)
                          • Respondent Demographics
                            • Practice Location: Gastroenterologists
                            • Practice Location: Rheumatologists
                            • Regional Association Under Which the Majority of Prescribing Is Conducted
                            • Number of Patients with CD or UC Under Management
                            • Number of Patients with RA, PsA, or AS Under Management
                            • Biologics Prescribed for RA by Rheumatologists
                            • Biologics Prescribed for PsA by Rheumatologists
                            • Drugs Prescribed for CD by Gastroenterologists
                            • Drugs Prescribed for UC by Gastroenterologists